RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?

Kurt Sartorius; Samuel O. Antwi; Anil Chuturgoon; Lewis R. Roberts; Anna Kramvis

doi:10.3389/fonc.2022.891812

RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?

Kurt Sartorius, Samuel O. Antwi, Anil Chuturgoon, Lewis R. Roberts, Anna Kramvis

Research output: Contribution to journal › Review article › peer-review

Abstract

Despite the early promise of RNA therapeutics as a magic bullet to modulate aberrant signaling in cancer, this field remains a work-in-progress. Nevertheless, RNA therapeutics is now a reality for the treatment of viral diseases (COVID-19) and offers great promise for cancer. This review paper specifically investigates RNAi as a therapeutic option for HCC and discusses a range of RNAi technology including anti-sense oligonucleotides (ASOs), Aptamers, small interfering RNA (siRNA), ribozymes, riboswitches and CRISPR/Cas9 technology. The use of these RNAi based interventions is specifically outlined in three primary strategies, namely, repressing angiogenesis, the suppression of cell proliferation and the promotion of apoptosis. We also discuss some of the inherent chemical and delivery problems, as well as targeting issues and immunogenic reaction to RNAi interventions.

Original language	English (US)
Article number	891812
Journal	Frontiers in Oncology
Volume	12
DOIs	https://doi.org/10.3389/fonc.2022.891812
State	Published - May 4 2022

Keywords

CRISPR/Cas9
RNAi strategies
antisense oligonucleotide (ASO)
aptamer
riboswitch
ribozyme
small interfering RNA (siRNA)

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3389/fonc.2022.891812

Cite this

@article{de3b849dc13e48cc81e9b82c2e79ff16,

title = "RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?",

abstract = "Despite the early promise of RNA therapeutics as a magic bullet to modulate aberrant signaling in cancer, this field remains a work-in-progress. Nevertheless, RNA therapeutics is now a reality for the treatment of viral diseases (COVID-19) and offers great promise for cancer. This review paper specifically investigates RNAi as a therapeutic option for HCC and discusses a range of RNAi technology including anti-sense oligonucleotides (ASOs), Aptamers, small interfering RNA (siRNA), ribozymes, riboswitches and CRISPR/Cas9 technology. The use of these RNAi based interventions is specifically outlined in three primary strategies, namely, repressing angiogenesis, the suppression of cell proliferation and the promotion of apoptosis. We also discuss some of the inherent chemical and delivery problems, as well as targeting issues and immunogenic reaction to RNAi interventions.",

keywords = "CRISPR/Cas9, RNAi strategies, antisense oligonucleotide (ASO), aptamer, riboswitch, ribozyme, small interfering RNA (siRNA)",

author = "Kurt Sartorius and Antwi, {Samuel O.} and Anil Chuturgoon and Roberts, {Lewis R.} and Anna Kramvis",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Sartorius, Antwi, Chuturgoon, Roberts and Kramvis.",

year = "2022",

month = may,

day = "4",

doi = "10.3389/fonc.2022.891812",

language = "English (US)",

volume = "12",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma

T2 - Dream or Reality?

AU - Sartorius, Kurt

AU - Antwi, Samuel O.

AU - Chuturgoon, Anil

AU - Roberts, Lewis R.

AU - Kramvis, Anna

PY - 2022/5/4

Y1 - 2022/5/4

N2 - Despite the early promise of RNA therapeutics as a magic bullet to modulate aberrant signaling in cancer, this field remains a work-in-progress. Nevertheless, RNA therapeutics is now a reality for the treatment of viral diseases (COVID-19) and offers great promise for cancer. This review paper specifically investigates RNAi as a therapeutic option for HCC and discusses a range of RNAi technology including anti-sense oligonucleotides (ASOs), Aptamers, small interfering RNA (siRNA), ribozymes, riboswitches and CRISPR/Cas9 technology. The use of these RNAi based interventions is specifically outlined in three primary strategies, namely, repressing angiogenesis, the suppression of cell proliferation and the promotion of apoptosis. We also discuss some of the inherent chemical and delivery problems, as well as targeting issues and immunogenic reaction to RNAi interventions.

AB - Despite the early promise of RNA therapeutics as a magic bullet to modulate aberrant signaling in cancer, this field remains a work-in-progress. Nevertheless, RNA therapeutics is now a reality for the treatment of viral diseases (COVID-19) and offers great promise for cancer. This review paper specifically investigates RNAi as a therapeutic option for HCC and discusses a range of RNAi technology including anti-sense oligonucleotides (ASOs), Aptamers, small interfering RNA (siRNA), ribozymes, riboswitches and CRISPR/Cas9 technology. The use of these RNAi based interventions is specifically outlined in three primary strategies, namely, repressing angiogenesis, the suppression of cell proliferation and the promotion of apoptosis. We also discuss some of the inherent chemical and delivery problems, as well as targeting issues and immunogenic reaction to RNAi interventions.

KW - CRISPR/Cas9

KW - RNAi strategies

KW - antisense oligonucleotide (ASO)

KW - aptamer

KW - riboswitch

KW - ribozyme

KW - small interfering RNA (siRNA)

UR - http://www.scopus.com/inward/record.url?scp=85130535454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130535454&partnerID=8YFLogxK

U2 - 10.3389/fonc.2022.891812

DO - 10.3389/fonc.2022.891812

M3 - Review article

AN - SCOPUS:85130535454

SN - 2234-943X

VL - 12

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 891812

ER -

RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this